Shanghai Allist Pharmaceuticals divulges new GTPase KRAS mutant inhibitors
Feb. 14, 2023
Shanghai Allist Pharmaceuticals Co. Ltd. has discovered pyridopyrimidines acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.